UroGen Pharma Ltd. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2017 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
UroGen Pharma Ltd. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2017 to Q4 2024.
  • UroGen Pharma Ltd. Net Income (Loss) Attributable to Parent for the quarter ending December 31, 2024 was -$37.5M, a 44.2% decline year-over-year.
  • UroGen Pharma Ltd. Net Income (Loss) Attributable to Parent for the twelve months ending December 31, 2024 was -$127M, a 24.1% decline year-over-year.
  • UroGen Pharma Ltd. annual Net Income (Loss) Attributable to Parent for 2024 was -$127M, a 24.1% decline from 2023.
  • UroGen Pharma Ltd. annual Net Income (Loss) Attributable to Parent for 2023 was -$102M, a 6.87% increase from 2022.
  • UroGen Pharma Ltd. annual Net Income (Loss) Attributable to Parent for 2022 was -$110M, a 0.94% increase from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 -$127M -$37.5M -$11.5M -44.2% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-10
Q3 2024 -$115M -$23.7M -$1.79M -8.2% Jul 1, 2024 Sep 30, 2024 10-K 2025-03-10
Q2 2024 -$114M -$33.4M -$9.27M -38.4% Apr 1, 2024 Jun 30, 2024 10-K 2025-03-10
Q1 2024 -$104M -$32.3M -$2.07M -6.86% Jan 1, 2024 Mar 31, 2024 10-K 2025-03-10
Q4 2023 -$102M -$26M +$2.85M +9.88% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-10
Q3 2023 -$105M -$21.9M +$3.95M +15.3% Jul 1, 2023 Sep 30, 2023 10-K 2025-03-10
Q2 2023 -$109M -$24.1M +$2.56M +9.57% Apr 1, 2023 Jun 30, 2023 10-K 2025-03-10
Q1 2023 -$112M -$30.2M -$1.82M -6.41% Jan 1, 2023 Mar 31, 2023 10-K 2025-03-10
Q4 2022 -$110M -$28.9M -$417K -1.47% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-14
Q3 2022 -$109M -$25.8M +$4.38M +14.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$114M -$26.7M -$469K -1.79% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$113M -$28.4M -$2.46M -9.47% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$111M -$28.5M +$2.07M +6.79% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-24
Q3 2021 -$113M -$30.2M -$1.4M -4.84% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$111M -$26.2M +$5.13M +16.4% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$117M -$25.9M +$11.9M +31.4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 -$128M -$30.5M +$8.45M +21.7% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-21
Q3 2020 -$137M -$28.8M -$6.56M -29.5% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$130M -$31.3M -$8.87M -39.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 -$121M -$37.8M -$16.3M -76.2% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 -$105M -$39M -$15.3M -64.3% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-02
Q3 2019 -$89.9M -$22.3M -$1.72M -8.37% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 -$88.2M -$22.5M -$4.45M -24.7% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 -$83.7M -$21.4M -$8.06M -60.2% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$75.7M -$23.7M -$13.6M -135% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-02
Q3 2018 -$62M -$20.5M -$20.2M -6790% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-02
Q2 2018 -$41.8M -$18M -$11.8M -191% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-02
Q1 2018 -$30M -$13.4M -$9.97M -292% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-02
Q4 2017 -$20M -$10.1M Oct 1, 2017 Dec 31, 2017 10-K 2019-02-28
Q3 2017 -$298K Jul 1, 2017 Sep 30, 2017 10-K 2019-02-28
Q2 2017 -$6.2M Apr 1, 2017 Jun 30, 2017 10-K 2019-02-28
Q1 2017 -$3.42M Jan 1, 2017 Mar 31, 2017 10-K 2019-02-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.